US 12,214,026 B2
Vaccine for falciparum malaria
Jonathan Kurtis, Providence, RI (US); Christian Parcher Nixon, Little Compton, RI (US); Dipak Kumar Raj, Pawtucket, RI (US); Jennifer Frances Friedman, Providence, RI (US); Michal Fried, Rockville, MD (US); and Patrick Emmet Duffy, Washington, DC (US)
Assigned to RHODE ISLAND HOSPITAL, Providence, RI (US); and SEATTLE CHILDREN'S HOSPITAL, Seattle, WA (US)
Filed by Rhode Island Hospital, Providence, RI (US); and Seattle Children's Hospital, Seattle, WA (US)
Filed on Jan. 13, 2023, as Appl. No. 18/154,642.
Application 18/154,642 is a division of application No. 17/178,111, filed on Feb. 17, 2021, granted, now 11,554,165.
Application 16/283,472 is a division of application No. 15/607,203, filed on May 26, 2017, granted, now 10,213,502, issued on Feb. 26, 2019.
Application 17/178,111 is a continuation of application No. 16/283,472, filed on Feb. 22, 2019, granted, now 10,960,065, issued on Mar. 30, 2021.
Application 15/607,203 is a continuation of application No. 14/361,573, granted, now 9,662,379, issued on May 30, 2017, previously published as PCT/US2012/067404, filed on Nov. 30, 2012.
Claims priority of provisional application 61/641,445, filed on May 2, 2012.
Claims priority of provisional application 61/566,365, filed on Dec. 2, 2011.
Prior Publication US 2023/0293654 A1, Sep. 21, 2023
Int. Cl. A61K 39/02 (2006.01); A61K 39/002 (2006.01); A61K 39/015 (2006.01); A61K 39/395 (2006.01); C07K 14/445 (2006.01); C07K 16/20 (2006.01); C07K 16/44 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/015 (2013.01) [A61K 39/39575 (2013.01); C07K 14/445 (2013.01); C07K 16/205 (2013.01); C07K 16/44 (2013.01); A61K 2039/505 (2013.01); A61K 2039/522 (2013.01); A61K 2039/54 (2013.01); A61K 2039/55 (2013.01); A61K 2039/575 (2013.01); C07K 2317/34 (2013.01); C07K 2317/76 (2013.01); Y02A 50/30 (2018.01)] 8 Claims
 
1. A method for reducing the severity of malaria or immunizing against malaria in a subject, comprising the step of administering a composition to the subject;
wherein the composition comprises a polypeptide selected from the group consisting of: CDPK5 (SEQ ID NO: 47), SERA5 (SEQ ID NOS: 70, 72), PfSUB1 (SEQ ID NO: 74), and PfPKG (SEQ ID NO: 76) or a combination of polypeptides thereof;
wherein the administration of the composition including the polypeptide or combination of polypeptides elicits an immune response to the polypeptide or combination of polypeptides;
wherein the immune response inhibits schizont egress from red blood cells;
thereby reducing the severity of malaria or immunizing against malaria in the subject.